Health Care [ 3/12 ] | Biotechnology [ 13/73 ]
NASDAQ | Common Stock
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.
Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis.
The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 25 | -0.21 Increased by +34.66% | -0.27 Increased by +22.22% |
| Aug 12, 25 | -0.27 Increased by +22.86% | -0.31 Increased by +12.90% |
| May 7, 25 | -0.26 Increased by +23.53% | -0.34 Increased by +23.91% |
| Mar 25, 25 | -0.33 Increased by 0.00% | -0.34 Increased by +1.52% |
| Nov 5, 24 | -0.32 Increased by +17.59% | -0.35 Increased by +8.17% |
| Aug 8, 24 | -0.35 Decreased by -9.37% | -0.34 Decreased by -2.94% |
| May 14, 24 | -0.34 Increased by +15.00% | -0.37 Increased by +8.11% |
| Mar 27, 24 | -0.33 Increased by +23.26% | -0.43 Increased by +23.26% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 5.00 K Increased by 0.00% | -19.01 M Increased by +16.77% | Decreased by -380.28 K% Increased by +16.77% |
| Jun 30, 25 | 5.00 K Increased by 0.00% | -22.15 M Increased by +10.12% | Decreased by -442.92 K% Increased by +10.12% |
| Mar 31, 25 | 5.00 K Increased by 0.00% | -19.57 M Increased by +19.75% | Decreased by -391.50 K% Increased by +19.75% |
| Dec 31, 24 | 5.00 K Decreased by -86.49% | -23.18 M Increased by +26.74% | Decreased by -463.60 K% Decreased by -442.12% |
| Sep 30, 24 | 5.00 K Decreased by -98.62% | -22.84 M Decreased by -10.52% | Decreased by -456.90 K% Decreased by -7.90 K% |
| Jun 30, 24 | 5.00 K Decreased by -16.67% | -24.64 M Decreased by -53.42% | Decreased by -492.80 K% Decreased by -84.10% |
| Mar 31, 24 | 5.00 K Decreased by -76.19% | -24.39 M Decreased by -21.52% | Decreased by -487.88 K% Decreased by -410.39% |
| Dec 31, 23 | 37.00 K Increased by +133.64% | -31.64 M Decreased by -46.08% | Decreased by -85.52 K% Decreased by -534.29% |